GenEdit Revenue and Competitors
Estimated Revenue & Valuation
- GenEdit's estimated annual revenue is currently $10.2M per year.
- GenEdit's estimated revenue per employee is $155,000
- GenEdit's total funding is $81M.
Employee Data
- GenEdit has 66 Employees.
- GenEdit grew their employee count by 8% last year.
GenEdit's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Co-founder | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Chief Business Development Officer | Reveal Email/Phone |
4 | SVP Business Operations & Co-founder | Reveal Email/Phone |
5 | Senior Director Corporate Strategy | Reveal Email/Phone |
6 | Director, Program Management | Reveal Email/Phone |
7 | Associate Project Manager | Reveal Email/Phone |
8 | Principal Scientist | Reveal Email/Phone |
9 | Scientist II | Reveal Email/Phone |
10 | Associate Scientist | Reveal Email/Phone |
GenEdit Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.2M | 3 | N/A | N/A | N/A |
#2 | $668.1M | 3337 | -4% | $1B | N/A |
#3 | $19.4M | 134 | -11% | N/A | N/A |
#4 | $0.6M | 8 | N/A | N/A | N/A |
What Is GenEdit?
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications. In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, current CRISPR delivery methods rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. A non-viral CRISPR/Cas9 delivery method is needed. In addition, low efficiency levels achieved make it impossible to target certain diseases. GenEdit's novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.
keywords:N/A$81M
Total Funding
66
Number of Employees
$10.2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.6M | 66 | N/A | N/A |
#2 | $5.1M | 66 | 5% | $166.7M |
#3 | $10.4M | 67 | 31% | N/A |
#4 | $12.7M | 69 | 6% | N/A |
#5 | $24M | 69 | -4% | $1.3B |